PHILADELPHIA--(BUSINESS WIRE)--Chimeron Bio, an RNA company developing self-amplifying RNA (saRNA) vaccines and therapeutics designed on its proprietary ChaESAR™ RNA delivery platform, announced today that Kevin Heyeck had been named Chief Executive Officer. Kevin comes to Chimeron with a long and successful track record of executive and entrepreneurial experience in life sciences.
Kevin began his career at Harvard University’s Office of Technology Licensing, then went on to lead corporate and business development for multiple venture-backed drug discovery companies, and more recently in venture capital as Managing Director of a venture fund investing in early-stage life science companies. In addition to joining the Chimeron Board, his board memberships include Cru Bio, UAMS Bioventures, and previously, Hibercell, Ultivue, and board observer of Iteos. Kevin’s guidance and leadership are informed by more than 25 years of experience starting and growing venture-backed life sciences companies, both in an executive capacity and as a serial entrepreneur.
“Kevin Heyeck possesses a rare blend of vision and operational knowledge that will support Chimeron Bio in achieving its next phase of growth. In addition to his experience in venture capital, executive leadership, and entrepreneurial success founding and building life sciences companies, Kevin has hands on experience heading corporate and business development for innovative life sciences companies including Allocure, Vitae Pharmaceuticals and Pharmacopeia,” said Afshin Safavi, Ph.D., Chairman of the Board at Chimeron Bio. Afshin continued, “Kevin’s business development perspective will prove invaluable to Chimeron Bio as we continue on our own growth journey and advance our mission to bring novel, accessible RNA therapies to patients across indications.”
“Chimeron Bio represents a ground-breaking company deploying a next-generation, foundational technology platform that pushes the frontier of RNA delivery and RNA medicines and will allow us to quickly build a high impact pipeline that includes pre-clinical studies in oncology, infection disease, and rare disease. I am looking forward to working with Chimeron’s exceptional team to advance the development of its self-amplifying RNA (saRNA) technology across indications using the ChaESAR™ platform to create and deliver innovative RNA medicines that will have a meaningful and positive impact for patients,” said Kevin Heyeck, new CEO of Chimeron Bio.
About Chimeron Bio
Chimeron Bio is a biotechnology company focused on the research of self-amplifying RNA (saRNA) towards development of novel RNA drugs and vaccines for various diseases. The company uses its proprietary ChaESAR™ platform to develop a pipeline in oncology, rare genetic disorders, and infectious diseases. It is developing two COVID-19 vaccine candidates each with its unique mechanism of action. The candidates have shown strong promise in early safety assessment and are under further development. For more information, visit www.chimeron.com.
